Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings : a mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020-2022
© 2023. The Author(s)..
INTRODUCTION: Australia has experienced sustained reductions in hepatitis C testing and treatment and may miss its 2030 elimination targets. Addressing gaps in community-based hepatitis C prescribing in priority settings that did not have, or did not prioritise, hepatitis C testing and treatment care pathways is critical.
METHODS: The Tasmanian Eliminate Hepatitis C Australia Outreach Project delivered a nurse-led outreach model of care servicing hepatitis C priority populations in the community through the Tasmanian Statewide Sexual Health Service, supported by the Eliminating Hepatitis C Australia partnership. Settings included alcohol and other drug services, needle and syringe programs and mental health services. The project provided clients with clinical care across the hepatitis C cascade of care, including testing, treatment, and post-treatment support and hepatitis C education for staff.
RESULTS: Between July 2020 and July 2022, a total of 43 sites were visited by one Clinical Nurse Consultant. There was a total of 695 interactions with clients across 219 days of service delivery by the Clinical Nurse Consultant. A total of 383 clients were tested for hepatitis C (antibody, RNA, or both). A total of 75 clients were diagnosed with hepatitis C RNA, of which 95% (71/75) commenced treatment, 83% (62/75) completed treatment and 52% (39/75) received a negative hepatitis C RNA test at least 12 weeks after treatment completion.
CONCLUSIONS: Providing outreach hepatitis C services in community-based services was effective in engaging people living with and at-risk of hepatitis C, in education, testing, and care. Nurse-led, person-centred care was critical to the success of the project. Our evaluation underscores the importance of employing a partnership approach when delivering hepatitis C models of care in community settings, and incorporating workforce education and capacity-building activities when working with non-specialist healthcare professionals.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC public health - 23(2023), 1 vom: 20. Nov., Seite 2289 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dawe, Joshua [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
63231-63-0 |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 16.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12889-023-17066-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364773715 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364773715 | ||
| 003 | DE-627 | ||
| 005 | 20240116231924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12889-023-17066-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM364773715 | ||
| 035 | |a (NLM)37985979 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dawe, Joshua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings |b a mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020-2022 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a INTRODUCTION: Australia has experienced sustained reductions in hepatitis C testing and treatment and may miss its 2030 elimination targets. Addressing gaps in community-based hepatitis C prescribing in priority settings that did not have, or did not prioritise, hepatitis C testing and treatment care pathways is critical | ||
| 520 | |a METHODS: The Tasmanian Eliminate Hepatitis C Australia Outreach Project delivered a nurse-led outreach model of care servicing hepatitis C priority populations in the community through the Tasmanian Statewide Sexual Health Service, supported by the Eliminating Hepatitis C Australia partnership. Settings included alcohol and other drug services, needle and syringe programs and mental health services. The project provided clients with clinical care across the hepatitis C cascade of care, including testing, treatment, and post-treatment support and hepatitis C education for staff | ||
| 520 | |a RESULTS: Between July 2020 and July 2022, a total of 43 sites were visited by one Clinical Nurse Consultant. There was a total of 695 interactions with clients across 219 days of service delivery by the Clinical Nurse Consultant. A total of 383 clients were tested for hepatitis C (antibody, RNA, or both). A total of 75 clients were diagnosed with hepatitis C RNA, of which 95% (71/75) commenced treatment, 83% (62/75) completed treatment and 52% (39/75) received a negative hepatitis C RNA test at least 12 weeks after treatment completion | ||
| 520 | |a CONCLUSIONS: Providing outreach hepatitis C services in community-based services was effective in engaging people living with and at-risk of hepatitis C, in education, testing, and care. Nurse-led, person-centred care was critical to the success of the project. Our evaluation underscores the importance of employing a partnership approach when delivering hepatitis C models of care in community settings, and incorporating workforce education and capacity-building activities when working with non-specialist healthcare professionals | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Australia | |
| 650 | 4 | |a Direct-acting antivirals | |
| 650 | 4 | |a Hepatitis C | |
| 650 | 4 | |a Nurse-led model of care | |
| 650 | 4 | |a People who inject drugs | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Hughes, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Shannon |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Louisa |e verfasserin |4 aut | |
| 700 | 1 | |a Richmond, Jacqueline A |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrana, Alisa |e verfasserin |4 aut | |
| 700 | 1 | |a Wilkinson, Anna L |e verfasserin |4 aut | |
| 700 | 1 | |a Owen, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Doyle, Joseph S |e verfasserin |4 aut | |
| 700 | 0 | |a EC Australia Partnership |e verfasserin |4 aut | |
| 700 | 1 | |a Hellard, Margaret |e investigator |4 oth | |
| 700 | 1 | |a Stoove, Mark |e investigator |4 oth | |
| 700 | 1 | |a Scott, Nick |e investigator |4 oth | |
| 700 | 1 | |a Howell, Jess |e investigator |4 oth | |
| 700 | 1 | |a Selvey, Linda |e investigator |4 oth | |
| 700 | 1 | |a Michaels, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Crawford, Sione |e investigator |4 oth | |
| 700 | 1 | |a Fowlie, Carrie |e investigator |4 oth | |
| 700 | 1 | |a Singhal, Shweta |e investigator |4 oth | |
| 700 | 1 | |a Davies, Jane |e investigator |4 oth | |
| 700 | 1 | |a Manu, Geoff |e investigator |4 oth | |
| 700 | 1 | |a Ward, James |e investigator |4 oth | |
| 700 | 1 | |a Drenkhahn, Geoff |e investigator |4 oth | |
| 700 | 1 | |a Bastian, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Dore, Greg |e investigator |4 oth | |
| 700 | 1 | |a Bryant, Mellissa |e investigator |4 oth | |
| 700 | 1 | |a Marshall, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Llyod, Andrew |e investigator |4 oth | |
| 700 | 1 | |a McMahon, Maria |e investigator |4 oth | |
| 700 | 1 | |a Sattell, Garry |e investigator |4 oth | |
| 700 | 1 | |a Casey, Dawn |e investigator |4 oth | |
| 700 | 1 | |a Shaw, David |e investigator |4 oth | |
| 700 | 1 | |a Rees, Tom |e investigator |4 oth | |
| 700 | 1 | |a Thompson, Alex |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMC public health |d 2001 |g 23(2023), 1 vom: 20. Nov., Seite 2289 |w (DE-627)NLM111200962 |x 1471-2458 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:20 |g month:11 |g pages:2289 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12889-023-17066-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 20 |c 11 |h 2289 | ||